You may register at via this link to the NCMLSG education symposium, school and group meeting here. Most welcome! See also “Events” page. Registration to the event For those who want to become or stay
ASH was as always hectic and stimulating. The CML oral sessions are very well summarized in the link from iCMLf below. Nothing very new here. The role of ASXL1 mutations are is maybe clarifying a
Ram Thakur and Göran Karlsson now publish a review on single cell techniques in CML in the prestigious Blood journal. This is a true feat and recognition of their work and insight in the fascinating
Stein Erik, who works in Bergen on mass cytometry, received the The ESH International John Goldman Research Award for 2025 accompanied with a grant of 80.000€. Well done and congratulations from the group. Image courtesy
The NCMLSG celebrates former Steering Board member Satu with this recognition of her long time work in CML immunology. The prize was awarded in Estoril Portugal at the European Scholl of Hematology meeting early October.
Register for renewed membership You need to register again for the new web site and since our old members list is outdated. With an account you can save your details for quicker registrations, and access
Our events bring together clinicians, nurses, scientists, and partners to share the latest in CML care and research. Explore the calendar, learn more about each session, and secure your spot with quick registration.
We aim is to cure CML patients without allogeneic transplantation and improve treatment of CML .
Our group consists of scientists, clinicians and nurses interested in CML. We work all over the Nordic region, mainly at University Hospitals but also hematologists working in other hospitals are active in our group. We meet twice a year (generally April and November).
Our activities have been supported by partners in pharmaceutical industry, and we regard this cooperation as an essential element for progress
We will pursue our aim by conducting clinical trials and attached to such trials address scientific questions in the laboratory. Sampling of patient material during trials is key to solve scientific problems that may direct us toward new treatments.
Our clinical trials have been focused on use of different tyrosine kinase inhibitors, also combined with pegylated interferon. For patients who do well we have participated in discontinuation projects (we contributed 25% of patients to the big EuroSKI project, an European LeukemiaNet study. See http://www.leukemia-net.org
Guideline-based treatment depends on excellent assessment of disease burden. Standardization efforts for PCR measurement of residual disease have been carried out and continue in anEuropean framework (EUTOS).
Spread of knowledge through education activities, with CML school for young hematologists and an open CML Education Symposium have been arranged every second year. Treatment guidelines have been issued in all countries and on the European level.
Henrik Hjorth-Hansen,
NCMLSG – chairman
The Nordic CML Study Group (NCMLSG) is guided by a dedicated team of experts in hematology, research, and clinical practice. Our steering group consists of leading specialists from across the Nordic region, committed to advancing the treatment of Chronic Myeloid Leukemia (CML).
Chairman, Trondheim
Helsinki
Roskilde
We are committed to advancing medical knowledge and collaboration. Whether you have questions, wish to contribute, or need further information about our study group, we’d love to hear from you. Connect with us to join a network of dedicated professionals striving for excellence in healthcare.